A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : SLAM / Systemic Lupus Activity Measure

[Related PubMed/MEDLINE]
Total Number of Papers: 91
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   SLAM  (>> Co-occurring Abbreviation)
Long Form:   Systemic Lupus Activity Measure
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. IFNs, SLE, SLEDAI
2019 Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Results from LUMINA (LXXVIII), a multiethnic, multicenter US cohort. CI, LDAS, LUMINA, SLE
2019 Self-reported disease severity in women with systemic lupus erythematosus. ACR, SLE, SLICC
2018 Study of Antichromatin Antibodies As A Marker of Lupus Activity and Lupus Nephritis. RF, SLE
2017 A comparison of patients' and physicians' assessments of disease activity using the Swedish version of the Systemic Lupus Activity Questionnaire. IQR, SLAQ, SLE
2016 Signal transducer and activator of transcription 5 is implicated in disease activity in adult and juvenile onset systemic lupus erythematosus. JAK/STAT, pSTAT5, SLE
2016 The implication of tissue Doppler echocardiography and cardiopulmonary exercise in early detection of cardiac dysfunction in systemic lupus erythematosus patients. aCL, ACR, CPX, LV, PW, QOL, RV, SLE, SLICC, TAPSE, TDE
2015 Serum neuron specific enolase - a novel indicator for neuropsychiatric systemic lupus erythematosus? ACR, NP, NPSLE, NSE, SLE
2014 Exhaled IL-8 in systemic lupus erythematosus with and without pulmonary fibrosis. BALF, EBC, HRCT, IL-8, SLE
10  2014 Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care. BICLA, BILAG, BILD, ECLAM, LAI, LDIQ, LupusPRO, RAPID3, RIFLE, SF36, SLAQ, SLE, SLEDAI, SRI
11  2013 A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus. HCQ, SLE
12  2013 Exhaled cytokines in systemic lupus erythematosus with lung involvement. BALF, EBC, IL, SLE
13  2013 [Myocardial remodeling in systemic lupus erythematosus and systemic scleroderma]. DD, ECLAM, LV, RD, SDS, SLE
14  2012 An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life. HADS, HRQoL, SLE, SLEDAI, SLICC/ACR
15  2011 Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). BILAG, ECLAM, SLEDAI
16  2011 Psychiatric disorders in patients with systemic lupus erythematosus: association of anxiety disorder with shorter disease duration. ACR, CDT, CNS, MMSE, NPSLE, SLE
17  2011 Quantitative data for care of patients with systemic lupus erythematosus in usual clinical settings: a patient Multidimensional Health Assessment Questionnaire and physician estimate of noninflammatory symptoms. BILAG, ECLAM, MDHAQ, SLAQ, SLE, SLEDAI-2K
18  2011 Two systemic lupus erythematosus (SLE) global disease activity indexes--the SLE Disease Activity Index and the Systemic Lupus Activity Measure--demonstrate different correlations with activation of peripheral blood CD4+ T cells. SLE, SLEDAI
19  2010 Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. anti-dsDNA, E-C3d, SELENA, SLE, SLEDAI
20  2010 Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus. ECLAM, SLE, SLEDAI
21  2009 [Neurological disorders in systemic lupus erythematosus patients]. ---
22  2008 Aerobic capacity correlates to self-assessed physical function but not to overall disease activity or organ damage in women with systemic lupus erythematosus with low-to-moderate disease activity and organ damage. HRQL, SLE
23  2008 Association of angiotensin-converting enzyme gene dimorphisms with severity of lupus disease. ACE, ACR, SLE
24  2008 Reliability and validity of the Fatigue Severity Scale in Swedish for patients with systemic lupus erythematosus. FSS, SLAM-VAS, SLE
25  2008 Serum soluble interleukin-2 receptor alpha in systemic lupus erythematosus. SLE
26  2007 [Evaluation of systemic lupus erythematosus activity during pregnancy]. ECLAM, LAI-P, m-PGA, m-SLAM, SLE, SLEDAI, SLEPDAI
27  2006 Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. MEDs, SLE
28  2006 Headache, Raynaud's syndrome and serotonin receptor agonists in systemic lupus erythematosus. OR
29  2006 Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. GEE, PGA, SLE, SLICC-DI
30  2005 Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates. ANCA, LF, PMN, SD, SLE
31  2005 Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. BILAG, ECLAM, LAI, SLE, SLEDAI
32  2005 Lymphocyte apoptosis and macrophage function: correlation with disease activity in systemic lupus erythematosus. AL, ELISA, FITC, IFN-gamma, SLE
33  2005 Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus. SELENA, SLE, SLEDAI
34  2005 Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. ESR, GEE, LUMINA, PGA, SDI, SLE
35  2005 Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. aCL, aPL, CI, GEE, hs, LUMINA, OR, SLE
36  2005 Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. HCQ, HR, SDI, SLE
37  2004 B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. HACAs, SLE
38  2004 Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life? HRQoL, MCS, PCS, SLE, SLICC
39  2004 Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. SLE, SLICC
40  2004 Systemic lupus erythematosus and gouty arthritis: an uncommon association. SLE
41  2004 Systemic lupus erythematosus in three ethnic groups. XIV. Poverty, wealth, and their influence on disease activity. SLE
42  2003 Clinical, immunogenetic and outcome features of Hispanic systemic lupus erythematosus patients of different ethnic ancestry. SLE, SLICC
43  2003 Determinants of discordance between patients and physicians in their assessment of lupus disease activity. VAS
44  2003 Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies. SLAQ, SLE
45  2002 Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. DHEA, SLE, SLEDAI
46  2002 Psychological distress and changes in the activity of systemic lupus erythematosus. CES-D, ECLAM, SLE, SLEDAI
47  2002 Serum C4 levels in patients with systemic lupus erythematosus in remission. IFN-gamma, SLE, SLEDAI
48  2002 Systemic lupus erythematosus in three ethnic groups. XI. Sources of discrepancy in perception of disease activity: a comparison of physician and patient visual analog scale scores. SLE, VAS
49  2001 A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. M-BILAG, M-LAI, M-SLEDAI, OR, PGA, SLE
50  2001 Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. ELISA, SLE
51  2001 Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. anti-dsDNA, ELISAs, M-BILAG, M-LAI, M-SLEDAI, PGA, SLE
52  2001 Longitudinal study of interleukin-10, tumor necrosis factor-alpha, anti-U1-snRNP antibody levels and disease activity in patients with mixed connective tissue disease. MCTD
53  2001 Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. SLAM-R, SLE
54  2001 Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. SLE, SLICC
55  2001 The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. BP, GH, MH, PF, RP, SF-36, SLE, SLEDAI, SLICC/ACR
56  2001 Variable effects of social support by race, economic status, and disease activity in systemic lupus erythematosus. SLE, SLICC/ACR
57  2000 Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. BILAG, ECLAM, LAI, SLE, SLEDAI, SRM
58  2000 Cytokine production, serum levels and disease activity in systemic lupus erythematosus. IL-4, PBMC, PHA, SLE, SLEDAI
59  2000 Measuring the activity of the disease in patients with cutaneous lupus erythematosus. D-DLE, L-DLE, LE, SCLE
60  2000 Serum thrombomodulin-a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity. ANA, CRP, ESR, ICAM-1, RIA, SLE, VCAM-1
61  2000 The rating scale preference measure as an evaluative measure in systemic lupus erythematosus. BILAG, ECLAM, SLE, SLEDAI
62  1999 A study of 20 SLE patients with intravenous immunoglobulin--clinical and serologic response. Abs, ANA, ENA, IVIG, SLE
63  1999 Outcome measures to be used in clinical trials in systemic lupus erythematosus. ACR, BILAG, ECLAM, HAQ, HRQoL, LAI, RCT, SIS, SLE, SLEDAI, SLICC
64  1999 Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. ES, ESI, REI, RS, SLE, SRM
65  1998 Dehydroepiandrosterone in systemic lupus erythematosus: relationship between dosage, serum levels, and clinical response. DHEA, DHEAS, SLE
66  1998 Increased serum levels of immunoglobulins, C-reactive protein, type 1 and type 2 cytokines in patients with mixed connective tissue disease. CRP, IFN-gamma, IL-10, MCTD, RA, SLE, TNF-alpha
67  1998 Socioeconomic status and health in women with systemic lupus erythematosus. HAQ, SES, SLE, SLEDAI, SLICC/ACR
68  1998 Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture. DR3, DR8, SLE
69  1998 Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. LUMINA Study Group. Lupus in minority populations, nature versus nurture. SLE
70  1998 [Soluble tumor necrosis factor receptors in patients with systemic lupus erythematosus]. sR-TNF
71  1997 Assessment of systemic lupus erythematosus disease activity by medical record review compared with direct standardized evaluation. SLE
72  1997 Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. CRP, IL, IL-1ra, RA, SLE, SpA, TNF
73  1996 High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. IVIG, SLE
74  1996 Outpatient monthly oral bolus cyclophosphamide therapy in systemic lupus erythematosus. SLE
75  1996 Prolactin hormone in juvenile systemic lupus erythematosus: a possible relationship to disease activity and CNS manifestations. CNS, PRL, SLE
76  1996 Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. PGA, SLEDAI
77  1996 Serum and urinary interleukin-6 in systemic lupus erythematosus. ELISA, SLE
78  1996 Ultraviolet-A1 (340-400 nm) irradiation therapy in systemic lupus erythematosus. SLE, UV-A1
79  1995 A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus. IL-2R, LTE4, SLE
80  1995 Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus. Relationship with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy. CRP, ECLAM, PAI, SLE, tPA
81  1995 Measurement of clinical activity of systemic lupus erythematosus and laboratory abnormalities: a 12-month prospective study. OR, SLE
82  1995 Posture in systemic lupus erythematosus. FET, SLE
83  1994 Fibromyalgia syndrome and disease activity in systemic lupus erythematosus. FS, SLE, VAS
84  1994 Indicators of disease activity, prognosis, and treatment of systemic lupus erythematosus. BILAG, ECLAM, LAI, SLE
85  1994 Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. BILAG, SLE, SLEDAI
86  1994 Serum thrombomodulin. A novel marker of disease activity in systemic lupus erythematosus. ACR, NYHSS, SLE, sTM
87  1992 Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. BILAG, SLE, SLEDAI
88  1992 Serological detection of disease activity in SLE. ---
89  1991 Quantitative clinical assessment of disease activity in systemic lupus erythematosus: progress report and research agenda. ARA, BILAG, SLE, SLEDAI
90  1990 [Evaluation of the clinical activity of systemic lupus erythematosus]. BILAG
91  1989 Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. BILAG, NIH, SLE, SLE-DAI